Kane Biotech (TSE:KNE) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Kane Biotech Inc. has entered into a global licensing agreement with Omni Bioceutical Innovations for the distribution of its coactiv+™ scalp care product line. The five-year deal allows Omni to market Kane’s innovative scalp detoxifier under their brand, targeting the medical aesthetics market. The partnership is poised to leverage the product’s proven efficacy in addressing common scalp conditions without harsh chemicals.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
